- Home
- ONB vs LEGN Comparison
ONB vs LEGN Comparison
Compare ONB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONB
- LEGN
- Stock Information
- Founded
- ONB 1834
- LEGN 2014
- Country
- ONB United States
- LEGN United States
- Employees
- ONB N/A
- LEGN N/A
- Industry
- ONB Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ONB Finance
- LEGN Health Care
- Exchange
- ONB Nasdaq
- LEGN Nasdaq
- Market Cap
- ONB 8.1B
- LEGN 6.3B
- IPO Year
- ONB N/A
- LEGN 2020
- Fundamental
- Price
- ONB $21.08
- LEGN $32.02
- Analyst Decision
- ONB Buy
- LEGN Strong Buy
- Analyst Count
- ONB 11
- LEGN 12
- Target Price
- ONB $26.27
- LEGN $70.82
- AVG Volume (30 Days)
- ONB 6.2M
- LEGN 1.5M
- Earning Date
- ONB 10-22-2025
- LEGN 11-11-2025
- Dividend Yield
- ONB 2.66%
- LEGN N/A
- EPS Growth
- ONB 2.73
- LEGN N/A
- EPS
- ONB 1.69
- LEGN N/A
- Revenue
- ONB $2,110,915,000.00
- LEGN $796,838,000.00
- Revenue This Year
- ONB $45.21
- LEGN $70.27
- Revenue Next Year
- ONB $15.25
- LEGN $50.28
- P/E Ratio
- ONB $12.43
- LEGN N/A
- Revenue Growth
- ONB 20.70
- LEGN 74.75
- 52 Week Low
- ONB $16.83
- LEGN $27.34
- 52 Week High
- ONB $24.49
- LEGN $47.79
- Technical
- Relative Strength Index (RSI)
- ONB 47.38
- LEGN 43.58
- Support Level
- ONB $20.47
- LEGN $31.60
- Resistance Level
- ONB $21.71
- LEGN $33.09
- Average True Range (ATR)
- ONB 0.77
- LEGN 1.48
- MACD
- ONB -0.03
- LEGN 0.08
- Stochastic Oscillator
- ONB 50.59
- LEGN 31.02
About ONB Old National Bancorp
Old National Bancorp with almost $10 billion in assets following its latest acquisition, Old National Bancorp is a financial services bank holding company headquartered in Indiana. Based in Evansville, Ind., Old National owns multiple financial services operations in Indiana, Illinois, and Kentucky. The company provides a group of similar community banking services, including such products and services as commercial, real estate, and consumer loans; deposits; and brokerage, trust, and investment advisory services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.